Articles

While disparities in healthcare exist, this panel will focus on disparities in cancer care from investigational research to disease treatment. Beyond just exploring the data and facts, this panel will recommend creative action to address and cure disparities that exist in cancer care.

Incubators and accelerators form a part of the entrepreneurial ecosystem in the healthcare industry and act as intermediaries between startups and established healthcare organizations. They are the proof of concept needed to gain additional investment, coverage and reimbursement and ultimately access to patients of often life-saving products and treatment.

This session will detail the Federal Trade Commission looking into pharmacy benefit managers.

Cancer research, just like other parts of the cancer ecosystem, suffered through COVID but the good news is research programs are back. Although researchers are back on the bench, there’s still a tremendous need to find funding for research programs. Research programs are recovering, but still there is great need to fund young investigator research programs and early on discovery programs.

An inside look at how senior executives from different Stakeholders in the cancer care community develop, evaluate, bring to market and drive, control, or mitigate utilization of a drug/biologic. Experts will discuss how researchers and biopharma companies work to see the drug/biologic achieve maximum potential from a business standpoint.

Panel discussion on the utilization of pathways in precision medicine, which has emerged as a way to deliver personalized, comprehensive care to cancer patients. As more healthcare organizations implement pathways and precision medicine strategies for screening, early stage and metastatic disease several challenges exist incorporating into routine clinical care.

In cancer care today, 70% to 80% of the total cost of care is incurred by ingredient costs from innovative pharmaceutical therapies. Truly, drug cost and pricing is the 800-pound gorilla in the room. This panel will discuss the Current and Future State of Value-Based Contracting in Cancer Care specific to the responsibility of all players in the cancer care ecosystem to create a responsible and viable path forward.

Patient navigators have been assisting persons with cancer for over two decades and now is the time to promote and vocalize the business case for a patient-centered approach to cancer care. Demonstrating the value of navigation is an essential step in determining the sustainability of patient navigation programs.

This session will detail new site of cancer care models.

Panelists will discuss the future of biosimilars in cancer care.